A drug called streptozocin is used to treat pancreatic cancer that has spread to other parts of the body

 



  For advanced islet-cell carcinoma, the combination of streptozocin and fluorouracil has become the standard treatment. However, doxorubicin, a drug that is structurally similar to streptozocin but causes less vomiting, has also been shown to be effective against this type of tumor.

  We randomly assigned 105 patients with advanced islet-cell carcinoma to one of three treatment regimens in this multicenter trial: streptozocin plus fluorouracil, streptozocin plus doxorubicin, or chlorozotocin alone. The 31 patients who did not respond to the treatment were switched to chlorozotocin alone or one of the combination regimens.

What is the purpose of Streptozocin?

Streptozocin is used to treat pancreas cancer that has progressed or spread to other parts of the body. Streptozocin belongs to a class of drugs known as alkylating agents. It works by slowing or stopping cancer cell growth in your body.

Where can I find streptozotocin?

Streptozotocin (STZ) is a naturally occurring chemical derived from Streptomyces achromogenes that is particularly toxic to the pancreatic insulin-producing beta cells in mammals.

 

  Streptozocin was discovered to be selectively toxic to pancreatic islet beta cells, which normally regulate blood glucose levels by producing the hormone insulin. This suggested that the drug could be used as an animal model of diabetes and as a medical treatment for beta-cell cancers. The National Cancer Institute investigated the use of streptozocin in cancer chemotherapy in the 1960s and 1970s. In November 1976, Upjohn applied to the FDA for approval of streptozocin as a treatment for pancreatic islet cell cancer, and approval was granted in July 1982. The drug was later marketed under the brand name Zanosar.

  More recently, a growing body of research has shown that insulin signaling dysfunction in type 2 diabetes significantly increases the risk of cognitive impairment and Alzheimer's disease (AD) progression. On this basis, direct administration of STZ into the brain (i.e., intracerebroventricular (ICV) infusion) has been used to develop an animal model of brain insulin resistance in rodents to mimic the pathophysiology of sporadic AD, which is the most common type of AD in humans.

Paperblog

Comments

Popular posts from this blog

Total Disc Replacement complete details Of Competitive Landscape Executive Summary Development in next decade

Dengue Vaccines development and progress towards vaccine has increased over the past few years

Marine electronics are electronic devices specifically designed for use in marine environments